Reply

Christine E. McLaren, James C. Barton, Pradyumna D. Phatak, Mary J. Emond, V. Nathan Subramaniam, Lyle C. Gurrin, Paul C. Adams, Lawrie W. Powell, Grant A. Ramm, Gregory J. Anderson, Gordon D. McLaren – 29 September 2015

Differing impact of the deletion of hemochromatosis‐associated molecules HFE and transferrin receptor‐2 on the iron phenotype of mice lacking bone morphogenetic protein 6 or hemojuvelin

Chloé Latour, Céline Besson‐Fournier, Delphine Meynard, Laura Silvestri, Ophélie Gourbeyre, Patricia Aguilar‐Martinez, Paul J. Schmidt, Mark D. Fleming, Marie‐Paule Roth, Hélène Coppin – 25 September 2015 – Hereditary hemochromatosis, which is characterized by inappropriately low levels of hepcidin, increased dietary iron uptake, and systemic iron accumulation, has been associated with mutations in the HFE, transferrin receptor‐2 (TfR2), and hemojuvelin (HJV) genes.

Long‐term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study

Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong, Judy Ching‐Lam Yeung, Chloe Yuk‐Kiu Fung, Jasmine Ka‐Lei Chan, Zoe Hoi‐Yi Chang, Chelsia Tsz‐Yan Kwan, Hiu‐Wan Lam, Jenny Limquiaco, Angel Mei‐Ling Chim, Cheuk‐Man Yu, Henry Lik‐Yuen Chan – 25 September 2015 – There is ongoing debate on whether screening for nonalcoholic fatty liver disease (NAFLD) is worthwhile in high‐risk groups. Because of shared risk factors, NAFLD is highly prevalent in patients with coronary artery disease.

Subscribe to